V. de Luque
5 Papers
19 Citations
V. de Luque is an academic researcher. The author has contributed to research in topics: Cancer & Hypoxia-inducible factors. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer.
Bella Pajares,L. Perez-Villa,Jose Manuel Trigo,M. D. Toledo,Martina Alvarez,Begoña Jimenez,J. A. Medina,V. de Luque,José M. Jerez,Emilio Alba +9 more
TL;DR: In this study, p16/HPV16-positive patients with LA-HNSCC treated with RT + EGFR inhibitors showed a better survival, not confirmed in multivariate analysis.
9
Hypoxia-inducible factor (HIF) 1α and 2α as predictive markers of outcome to VEGFR tyrosine kinase inhibitors (TKI) in renal cell carcinoma (RCC).
María Isabel Sáez,Jose Manuel Trigo Perez,Luis G. Perez-Rivas,L. Perez-Villa,R. Villatoro,A. Montesa,J.I. Cid,M. Leon,V. de Luque,Carolina Fernandez,Cristina Quero,Bella Pajares,Emilio Alba +12 more
TL;DR: Relevant biomarkers in RCC are needed to identify appropriate candidates for selected targeted therapies and mutations in the von Hippel-Lindau (VHL) gene result in the accumulation of HIF and increased expression of proangiogenic factors, including VEGF.
7
Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy.
Jaime Gómez-Millán,Bella Pajares,L. Perez-Villa,Amancio Carnero,Martina Alvarez,V. de Luque,F. Rivas,Jose Manuel Trigo,M. D. Toledo,Emilio Alba,J. A. Medina +10 more
TL;DR: Subcellular localisation of pMEK has different prognosis in locally advanced head and neck cancer treated with radiochemotherapy, and is predictive of worse DFS and OS outcomes.
Abstract P3-07-15: Prosigna® subtype correlation is a strong predictor of response to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) study
R Chica Parrado,Begoña Jiménez-Rodríguez,P. Sanchez Rovira,M. Alvarez,Luis Vicioso,Ana Inés Fernández,V. de Luque,M José Lozano,Ester Villar,Irene Zarcos,Cesar E. Ramirez,C González-Hermoso,Arthur Jeiranian,Naeem Dowidar,Carl Schaper,Wesley Buckingham,Sean Ferree,Nuria Ribelles,I. Rodrigo,Aleix Prat,Emiliano Zamora de Alba +20 more
1
Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patients
Angela Santonja,Nuria Ribelles,Begoña Jiménez-Rodríguez,P. Sanchez Rovira,M. Alvarez,Luis Vicioso,A Isabel Fernandez,V. de Luque,C. Fernandez de Sousa,Ester Villar,Irene Zarcos,Cesar E. Ramirez,C González-Hermoso,Arthur Jeiranian,Naeem Dowidar,Carl Schaper,Wesley Buckingham,Sean Ferree,Antonio Núñez Jiménez,Aleix Prat,Emiliano Zamora de Alba +20 more
TL;DR: The results of this study indicate that HER2+ patients with greater correlations to the HER2E subtype have an increased likelihood of response to combination neoadjuvant regimens that included HER2-targeted therapy.
1